Cullinan Therapeutics, Inc.
CGEMCIK 0001789972 · Biological Products, (No Diagnostic Substances) · Nasdaq
- Cullinan Oncology, Inc. (until 2024-04-02)
- Cullinan Management, Inc. (until 2021-02-22)
- Cullinan Oncology, LLC (until 2021-01-06)
Revenue (TTM)
$0
−100.0% YoY
Q1 Apr 2026
Net Income (TTM)
−$209.73M
−31.4% YoY
Q1 Apr 2026
EPS Diluted (TTM)
−$3.21
−255.0% YoY
Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$178.61M
Q1 Apr 2026
Cash
$75.08M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
61.46M sh
Q1 Apr 2026